Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62


Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.

Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS.

Int J Radiat Oncol Biol Phys. 2018 Apr 17. pii: S0360-3016(18)30680-1. doi: 10.1016/j.ijrobp.2018.04.023. [Epub ahead of print]


Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.

McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK.

Clin Cancer Res. 2018 May 30. doi: 10.1158/1078-0432.CCR-17-3577. [Epub ahead of print]


Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Gao X, Jegede O, Gray C, Catalano PJ, Novak J, Kwiatkowski DJ, McKay RR, George DJ, Choueiri TK, McDermott DF, Signoretti S, Bhatt RS.

Clin Genitourin Cancer. 2018 Apr 25. pii: S1558-7673(18)30164-2. doi: 10.1016/j.clgc.2018.04.001. [Epub ahead of print]


The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.


Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.

Bryant AK, D'Amico AV, Nguyen PL, Einck JP, Kane CJ, McKay RR, Simpson DR, Mundt AJ, Murphy JD, Rose BS.

Cancer. 2018 Jul 15;124(14):2939-2947. doi: 10.1002/cncr.31400. Epub 2018 May 4.


Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.


The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.

Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR.

Clin Genitourin Cancer. 2018 Apr;16(2):e327-e333. doi: 10.1016/j.clgc.2017.11.005. Epub 2017 Dec 6.


Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME.

Prostate Cancer Prostatic Dis. 2017 Dec 20. doi: 10.1038/s41391-017-0009-6. [Epub ahead of print]


Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database.

Hamieh L, McKay RR, Lin X, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Aug 12. pii: S1558-7673(17)30231-8. doi: 10.1016/j.clgc.2017.07.021. [Epub ahead of print]


Neoadjuvant therapy for localized and locally advanced renal cell carcinoma.

Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, Campbell SC, Rini BI, Derweesh IH.

Urol Oncol. 2018 Jan;36(1):31-37. doi: 10.1016/j.urolonc.2017.07.015. Epub 2017 Aug 10. Review.


Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.

Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):724-732. doi: 10.1016/j.clgc.2017.05.019. Epub 2017 May 31.


Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.


Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.

McKay RR, Werner L, Fiorillo M, Roberts J, Heath EI, Bubley GJ, Montgomery RB, Taplin ME.

Clin Genitourin Cancer. 2017 Aug;15(4):463-471. doi: 10.1016/j.clgc.2016.10.006. Epub 2016 Oct 27.


A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970.


Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy.

McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME.

Clin Genitourin Cancer. 2017 Apr;15(2):e289-e298. doi: 10.1016/j.clgc.2016.08.015. Epub 2016 Aug 20.


Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK.

J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print]


Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.

McKay RR, Werner L, Fiorillo M, Nakabayashi M, Kantoff PW, Taplin ME.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):398-405. doi: 10.1038/pcan.2016.31. Epub 2016 Aug 9.


Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.

Hamieh L, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Apr;15(2):221-229. doi: 10.1016/j.clgc.2016.06.017. Epub 2016 Jun 29.


CHALLENGE Trial 1 Year Feasibility Results-Letter.

Pernar CH, Markt SC, McKay RR, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1277. doi: 10.1158/1055-9965.EPI-16-0393. Epub 2016 Jul 14. No abstract available.


A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.

McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK.

Cancer. 2016 Aug 1;122(15):2389-98. doi: 10.1002/cncr.30056. Epub 2016 May 19.


Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.

Marmarelis ME, Davis MR, Sethi NS, Krajewksi KM, McKay RR, Choueiri TK, Ott PA.

J Immunother Cancer. 2016 Apr 19;4:26. doi: 10.1186/s40425-016-0129-x. eCollection 2016.


A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME.

J Clin Oncol. 2016 Jun 1;34(16):1913-20. doi: 10.1200/JCO.2015.65.3154. Epub 2016 Apr 4.


Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL.

Clin Genitourin Cancer. 2016 Aug;14(4):e299-305. doi: 10.1016/j.clgc.2015.12.008. Epub 2015 Dec 17.


Statins and survival outcomes in patients with metastatic renal cell carcinoma.

McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, Ghoroghchian PP, Bhatt RS, Kaffenberger SD, Simantov R, Choueiri TK, Heng DY.

Eur J Cancer. 2016 Jan;52:155-62. doi: 10.1016/j.ejca.2015.10.008. Epub 2015 Dec 11.


Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective.

Albiges L, Fay AP, McKay RR, Kaymakcalan MD, Choueiri TK.

Surg Pathol Clin. 2015 Dec;8(4):657-62. doi: 10.1016/j.path.2015.08.001. Review.


Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK.

Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5.


Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.

Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.

Cancer. 2015 Oct 1;121(19):3435-43. doi: 10.1002/cncr.29503. Epub 2015 Jun 8.


Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME.

Cancer. 2015 Aug 1;121(15):2603-11. doi: 10.1002/cncr.29398. Epub 2015 Apr 22.


Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.

Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK.

J Immunother Cancer. 2015 Feb 17;3:3. doi: 10.1186/s40425-015-0047-3. eCollection 2015.


Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK.

Clin Cancer Res. 2015 Jun 1;21(11):2471-9. doi: 10.1158/1078-0432.CCR-14-2332. Epub 2015 Feb 27.


Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients.

Sammon JD, McKay RR, Kim SP, Sood A, Sukumar S, Hayn MH, Hu JC, Kibel AS, Nguyen PL, Peabody JO, Saad F, Sun M, Varda B, Menon M, Choueiri TK, Trinh QD.

Urology. 2015 Feb;85(2):343-9. doi: 10.1016/j.urology.2014.09.053.


Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.

McKay RR, Mamlouk K, Montgomery B, Taplin ME.

Clin Genitourin Cancer. 2015 Aug;13(4):e325-8. doi: 10.1016/j.clgc.2014.12.015. Epub 2014 Dec 31. No abstract available.


Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.

Grünwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK.

Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7.


The burden of skeletal-related events in patients with prostate cancer and bone metastasis.

Roghmann F, Antczak C, McKay RR, Choueiri T, Hu JC, Kibel AS, Kim SP, Kowalczyk KJ, Menon M, Nguyen PL, Saad F, Sammon JD, Schmid M, Sukumar S, Sun M, Noldus J, Trinh QD.

Urol Oncol. 2015 Jan;33(1):17.e9-17.e18. doi: 10.1016/j.urolonc.2014.09.010. Epub 2014 Oct 30.


Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS.

Cancer. 2015 Jan 15;121(2):311-9. doi: 10.1002/cncr.28972. Epub 2014 Sep 18.


Mental health outcomes in elderly men with prostate cancer.

Ravi P, Karakiewicz PI, Roghmann F, Gandaglia G, Choueiri TK, Menon M, McKay RR, Nguyen PL, Sammon JD, Sukumar S, Varda B, Chang SL, Kibel AS, Sun M, Trinh QD.

Urol Oncol. 2014 Nov;32(8):1333-40. doi: 10.1016/j.urolonc.2014.05.005. Epub 2014 Aug 19.


Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin ME.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):325-31. doi: 10.1038/pcan.2014.28. Epub 2014 Aug 5.


Adrenocortical carcinoma: the management of metastatic disease.

Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK.

Crit Rev Oncol Hematol. 2014 Nov;92(2):123-32. doi: 10.1016/j.critrevonc.2014.05.009. Epub 2014 Jun 4. Review.


Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Fennessy FM, McKay RR, Beard CJ, Taplin ME, Tempany CM.

Transl Oncol. 2014 Feb 1;7(1):120-9. eCollection 2014 Feb.


Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.

McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK.

Eur Urol. 2014 Sep;66(3):502-9. doi: 10.1016/j.eururo.2014.02.040. Epub 2014 Feb 26.


Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer.

McKay RR, Taplin ME, Choueiri TK.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83, ix. doi: 10.1016/j.hoc.2013.08.009. Epub 2013 Sep 20. Review.


Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).

Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK.

BJU Int. 2014 May;113(5b):E67-74. doi: 10.1111/bju.12442. Epub 2014 Feb 14.


Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK.

Eur Urol. 2014 Mar;65(3):577-84. doi: 10.1016/j.eururo.2013.08.012. Epub 2013 Aug 15.


Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer.

McKay RR, Choueiri TK, Taplin ME.

Drugs. 2013 Sep;73(13):1417-30. doi: 10.1007/s40265-013-0107-2. Review.


Prostate cancer 2012: where do we stand and where are we heading?

McKay RR, Kantoff P.

Oncology (Williston Park). 2012 Dec;26(12):1222, 1224. No abstract available.


Autofocus methods of whole slide imaging systems and the introduction of a second-generation independent dual sensor scanning method.

Montalto MC, McKay RR, Filkins RJ.

J Pathol Inform. 2011;2:44. doi: 10.4103/2153-3539.86282. Epub 2011 Oct 19.


The accuracy of dynamic predictive autofocusing for whole slide imaging.

McKay RR, Baxi VA, Montalto MC.

J Pathol Inform. 2011;2:38. doi: 10.4103/2153-3539.84231. Epub 2011 Aug 24.


The application of Bayesian spectral analysis to optical sectioning using structured light imaging.

O Ruanaidh JJ, McKay RR, Zhang Y, Briggs M, George J, Masoumi Z.

J Microsc. 2008 Oct;232(1):177-85. doi: 10.1111/j.1365-2818.2008.02070.x.


A calmodulin/inositol 1,4,5-trisphosphate (IP3) receptor-binding region targets TRPC3 to the plasma membrane in a calmodulin/IP3 receptor-independent process.

Wedel BJ, Vazquez G, McKay RR, St J Bird G, Putney JW Jr.

J Biol Chem. 2003 Jul 11;278(28):25758-65. Epub 2003 May 2.

Supplemental Content

Loading ...
Support Center